Connect your AI

ARS Pharmaceuticals, Inc. SPRY Price / book

Price / book at other companies

Amneal Pharmaceuticals, Inc.AMRX

94.1×+93.1×

ViatrisVTRS

1.1×+0.4×

Catalyst PharmaceuticalCPRX

3×-0.7×

Eton Pharmaceuticals, Inc.ETON

22×+7.8×

Other financials

Income statement

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

Operating cash flow-$44.9M-10.3%

CapEx--100%

Free cash flow-$44.9M-10.1%

Valuation

Market cap$1.05B-32.6%

Enterprise value$1.12B-26.0%

P/S10.6×-5.4×

Profitability

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Where this comes from

Calculated from ARS Pharmaceuticals, Inc.’s reported figures.

market cap/total stockholders equity=13×

Based on the most recent quarter.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s price / book?: ARS Pharmaceuticals, Inc. (SPRY) reported price / book of 13× in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s price / book changed year-over-year?: ARS Pharmaceuticals, Inc.'s price / book increased by 141.3% year-over-year, from 5.4× to 13×.
What is the long-term trend for ARS Pharmaceuticals, Inc.'s price / book?: Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s price / book has grown at a 50.8% compound annual growth rate (CAGR), from 2.9× to 10.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.